Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3)
Nailfold Capillaroscopy in PH
Pulmonary hypertension (PH) is an uncommon condition and can often be difficult to diagnose. It means elevated blood pressure in the lungs which can rapidly lead to failure of the right side of the heart and is ultimately fatal.
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3), Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT07768644
- Testing
- Standard of Care therapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Glasgow
Pulmonary Hypertension, Elevated Mean Pulmonary Arterial Pressure
Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary Hypertension
Pulmonary hypertension (PH) is a life-threatening cardiovascular disease characterized by pathological elevation of mean pulmonary arterial pressure (mPAP) >/= 25 mmHg at rest.
- Conditions
- Pulmonary Hypertension, Elevated Mean Pulmonary Arterial Pressure, Normal Mean Pulmonary Arterial Pressure
- Trial name
- CMR-PH (NCT01725763)
- Testing
- Cardiac MRI
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- Medical University of Graz
Muscle Weakness, Pulmonary Arterial Hypertension
Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a disease that causes raised blood pressure in blood vessels that pick up oxygen from the lungs. It has a life expectancy similar to some cancers.
- Trial name
- NCT01847716
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Chronic Obstructive Pulmonary Disease
Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary
The Multi-Ethnic Study of Atherosclerosis (MESA) - Chronic Obstructive Pulmonary Disease (COPD) Study aims to characterize the pulmonary vascular changes and their biology in early COPD using imaging, gene expression profiling…
- Trial name
- MESA-COPD (NCT01397721)
- Where
- 4 sites in United States
- Volunteers
- 359 people
- Sponsor
- Columbia University
Emergency Department Patients, Pulmonary Hypertension
Pulmonary Artery Pressure in Predicting Pulmonary Embolism in Patients Presenting To The Emergency Department With Dyspnea
The aim of this study is to determine the usability of echocardiographic PAP changes obtained from emergency department records in the early risk stratification of pulmonary embolism.
- Conditions
- Emergency Department Patients, Pulmonary Hypertension, Pulmonary Embolism
- Trial name
- NCT07641400
- Testing
- Pulmonary embolism (+), pulmonary embolism (-)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Antalya Health Sciences University
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled safety/efficacy database of…
- Trial name
- NCT00796666
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 48 sites in United States, Argentina and 16 more
- Volunteers
- 131 people
- Sponsor
- Pfizer
Pulmonary Hypertension
Upfront Combination Pulmonary Arterial Hypertension Therapy
To evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT03809156
- Testing
- Riociguat Oral Product
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Pulmonary Arterial Hypertension, Pulmonary Hypertension
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
This trial is a study of Remodulin in patients with pulmonary arterial hypertension who have been transitioned from Flolan therapy. The study consists of Screening, Baseline and Treatment Phases.
- Trial name
- NCT00058929
- Testing
- treprostinil sodium
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension
In a group of patients with PAH treated with treprostinil, the current study aims to investigate the effect of treatment on RV structure and function; and correlate changes in RV structure and function with: World Health…
- Trial name
- NCT03835676
- Testing
- Treprostinil
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Magdi H. Yacoub
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Pulmonary Arterial Hypertension, Congenital Heart Disease
Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE
SUMMARY Rationale: Pulmonary arterial hypertension (PAH) can be a rapidly progressive disorder and is associated with a high mortality rate, despite medical intervention.
- Trial name
- BICYCLE (NCT01827059)
- Testing
- Bosentan
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hypertension, Pulmonary
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
The purpose of this study is to determine whether aspirin and simvastatin are safe and effective for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00384865
- Testing
- Simvastatin, Aspirin
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Pennsylvania
Schistosomiasis
Assessment of Right Ventricular-Pulmonary Arterial Coupling in Schistosomiasis-Associated Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension is a progressive and potentially fatal cardiopulmonary disorder characterized by remodeling of the pulmonary vasculature, progressive elevation of pulmonary vascular resistance (PVR), and eventual…
- Trial name
- Sch-PAH RV-PA (NCT07707193)
- Testing
- right heart catheterization for measure pulmonary artery pressure
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Hypertension, Pulmonary
THERAPY-HYBRID-BPA Trial
Riociguat could improve the exercise capacity and residual symptoms in patients with chronic thromboembolic pulmonary hypertension (CTEPH) even after normalization of pulmonary arterial pressure by balloon pulmonary angioplasty…
- Trial name
- NCT04600492
- Testing
- Riociguat Oral Tablet
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- National Hospital Organization Okayama Medical Center
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on Blood and Tissue Oxygenation (aBGA, NIRS)
Randomized crossover trial in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary Hypertension (CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above…
- Trial name
- NCT03637114
- Testing
- Simulated Altitude (FiO2: 15.1%)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension (PAH)
(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
Pilot study to determine the therapeutic effect of two prarallel groups treated with either Riciguat or Macitentan, evaluated by the change in systolic and diastolic RV function within 12 weeks after first drug intake in order to…
- Trial name
- RightHeartIII (NCT03362047)
- Testing
- Riciguat Group, Macitentan Group
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- University of Giessen
Pulmonary Arterial Hypertension
The Early Recognition of Pulmonary Arterial Hypertension
The early detection of pulmonary arterial hypertension may help to improve prognosis of the disease. It is assumed that in the early stages of pulmonary arterial hypertension, pulmonary arterial pressure values may be normal at…
- Trial name
- NCT00609349
- Testing
- ETED, CPET, RHC
- Where
- Austria
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Pulmonary Arterial Hypertension
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)
This study of frespaciguat in participants with Group 1 pulmonary arterial hypertension (PAH) will assess the safety, tolerability and pharmacokinetics (PK) of inhaled frespaciguat. There is no formal hypothesis to be tested.
- Trial name
- NCT03744637
- Testing
- Frespaciguat
- Where
- Moldova
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension, Precapillary Pulmonary Hypertension
Digital Assessment of Real-World Walking Activity in Pulmonary Hypertension: A Prospective Multicenter Trial
The goal of this observational study is to validate digital mobility outcomes for monitoring the treatment and disease progression in adult patients with pulmonary hypertension.
- Conditions
- Pulmonary Hypertension, Precapillary Pulmonary Hypertension, Right Heart Catheterisation, Digital Mobility Outcomes
- Trial name
- NCT07137260
- Testing
- Accelerometer (measurement of walking activity)
- Where
- 4 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Simon Jäger
Pulmonary Arterial Hypertension
Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets
Single dose oral bioequivalence study of Riociguat 2.5 mg film coated tablets and 'Adempas' (Riociguat) 2.5 mg Filmtabletten (film coated tablets) in healthy adult male subjects under fasting conditions.
- Trial name
- NCT06180096
- Testing
- Riociguat film coated tablets, Adempas Filmtabletten
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi